VAERS Explorer
Back to explore

Report #2895980

Received May 8, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Female
Age
74 yrs
State
TN
Recovered
Unknown
Vaccinated
Feb 1, 2026
Onset
Feb 1, 2026
Days to onset
0
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
VARZOSZOSTER (SHINGRIX)GLAXOSMITHKLINE BIOLOGICALS2——

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

late dose; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a 74-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received first dose in 0ct-2018). In FEB-2026, the patient received the 2nd dose of Shingrix. In FEB-2026, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: late dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date:01-MAY-2026 The batch number was not provided upon follow up with the reporter.